A systematic review of secretin for children with autism spectrum disorders
- PMID: 21464196
- PMCID: PMC3387870
- DOI: 10.1542/peds.2011-0428
A systematic review of secretin for children with autism spectrum disorders
Abstract
Context: As many as 1 in every 110 children in the United States has an autism spectrum disorder (ASD). Secretin is 1 of many medical treatments studied for treating the symptoms of ASDs, but there is currently no consensus regarding which interventions are most effective.
Objective: To systematically review evidence regarding the use of secretin in children with ASDs who are aged 12 years and younger.
Methods: We searched the Medline, PsycINFO, and ERIC (Education Resources Information Center) databases from 2000 to May 2010 and reference lists of included articles. Two reviewers independently assessed each study against predetermined inclusion/exclusion criteria. Two reviewers independently extracted data regarding participant and intervention characteristics, assessment techniques, and outcomes and assigned overall quality and strength-of-evidence ratings on the basis of predetermined criteria.
Results: Evidence from 7 randomized controlled trials supports a lack of effectiveness of secretin for the treatment of ASD symptoms including language and communication impairment, symptom severity, and cognitive and social skill deficits. No studies have resulted in significantly greater improvements in measures of language, cognition, or autistic symptoms when compared with placebo; study authors who reported improvement over time did so equally for both the intervention and placebo groups.
Conclusions: Secretin has been studied extensively in multiple randomized controlled trials, and there is clear evidence that it lacks benefit. The studies of secretin included in this review uniformly point to a lack of significant impact of secretin in the treatment of ASD symptoms. Given the high strength of evidence for a lack of effectiveness, secretin as a treatment approach for ASDs warrants no further study.
Figures
Comment in
-
Review: secretin is not effective for the treatment of children with autism spectrum disorders.Evid Based Ment Health. 2011 Nov;14(4):104. doi: 10.1136/ebmh.2011.100131. Epub 2011 Sep 27. Evid Based Ment Health. 2011. PMID: 21954153 No abstract available.
Similar articles
-
A systematic review of medical treatments for children with autism spectrum disorders.Pediatrics. 2011 May;127(5):e1312-21. doi: 10.1542/peds.2011-0427. Epub 2011 Apr 4. Pediatrics. 2011. PMID: 21464191 Review.
-
A systematic review of early intensive intervention for autism spectrum disorders.Pediatrics. 2011 May;127(5):e1303-11. doi: 10.1542/peds.2011-0426. Epub 2011 Apr 4. Pediatrics. 2011. PMID: 21464190 Review.
-
Intravenous secretin for autism spectrum disorders (ASD).Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD003495. doi: 10.1002/14651858.CD003495.pub3. Cochrane Database Syst Rev. 2012. PMID: 22513913 Free PMC article. Review.
-
Parent-mediated early intervention for young children with autism spectrum disorders (ASD).Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009774. doi: 10.1002/14651858.CD009774.pub2. Cochrane Database Syst Rev. 2013. PMID: 23633377 Review.
-
Medications for adolescents and young adults with autism spectrum disorders: a systematic review.Pediatrics. 2012 Oct;130(4):717-26. doi: 10.1542/peds.2012-0683. Epub 2012 Sep 24. Pediatrics. 2012. PMID: 23008452 Free PMC article. Review.
Cited by
-
Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2. Cochrane Database Syst Rev. 2023. PMID: 37811711 Free PMC article. Review.
-
Microbial stimulation of oxytocin release from the intestinal epithelium via secretin signaling.Gut Microbes. 2023 Dec;15(2):2256043. doi: 10.1080/19490976.2023.2256043. Gut Microbes. 2023. PMID: 37698879 Free PMC article.
-
Microbial stimulation of oxytocin release from the intestinal epithelium via secretin signaling.bioRxiv [Preprint]. 2023 Mar 9:2023.03.09.531917. doi: 10.1101/2023.03.09.531917. bioRxiv. 2023. Update in: Gut Microbes. 2023 Dec;15(2):2256043. doi: 10.1080/19490976.2023.2256043. PMID: 36945649 Free PMC article. Updated. Preprint.
-
Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial.Nat Med. 2022 Mar;28(3):528-534. doi: 10.1038/s41591-022-01683-9. Epub 2022 Feb 14. Nat Med. 2022. PMID: 35165451 Clinical Trial.
-
The Potential Role of Gut Peptide Hormones in Autism Spectrum Disorder.Front Cell Neurosci. 2020 Mar 31;14:73. doi: 10.3389/fncel.2020.00073. eCollection 2020. Front Cell Neurosci. 2020. PMID: 32296309 Free PMC article. Review.
References
-
- Tulassay Z, Bodnar A, Farkas I, Papp J, Gupta R. Somatostatin versus secretin in the treatment of actively bleeding gastric erosions. Digestion. 1992;51(4):211–216 - PubMed
-
- Watanabe Y, Tsumura H, Sasaki H. Effect of continuous intravenous infusion of secretin preparation (secrepan) in patients with hemorrhage from chronic peptic ulcer and acute gastric mucosal lesion (AGML). Gastroenterol Jpn. 1991;26(suppl 3):86–89 - PubMed
-
- Charlton CG, Miller RL, Crawley JN, Handelmann GE, O'Donohue TL. Secretin modulation of behavioral and physiological functions in the rat. Peptides. 1983;4(5):739–742 - PubMed
-
- Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9(1):9–15 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
